Teva Pharmaceutical Industries Ltd ADR (NYSE:TEVA) saw its stock climb 2.7% after announcing FDA approval and the U.S. launch of its generic version of Saxenda (liraglutide injection). This marks the first generic GLP-1 drug specifically approved for weight loss.
The new liraglutide injection addresses rising demand for weight management therapies in the United States. It is approved for adults with obesity or overweight who have weight-related medical conditions, as well as for pediatric patients aged 12–17 years weighing over 60 kg with obesity.
“With this approval, and by launching a generic for Saxenda (liraglutide injection), we will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss,” said Ernie Richardsen, SVP, Head of U.S. Commercial Generics at Teva.
This launch marks Teva’s fifth first-to-market generic entry this year, furthering the company’s “Pivot to Growth Strategy,” which focuses on complex generics. The reference product, Saxenda, had annual sales of $165 million as of June 2025.
Liraglutide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist that must be used alongside a reduced-calorie diet and increased physical activity. It is not recommended for individuals already taking liraglutide or other GLP-1 receptor agonists.
Teva Pharmaceutical Industries
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.